Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

Kieran F. DochertyPaul WelshSubodh VermaRudolf A. De BoerEileen O'MearaOlof BengtssonLars KøberMikhail N. KosiborodAnn HammarstedtAnna Maria LangkildeDaniel LindholmDustin J. LittleMikaela SjöstrandFelipe A. MartinezPiotr PonikowskiMarc S. SabatineDavid A. MorrowMorten SchouScott D. SolomonNaveed SattarPardeep S. JhundJohn J.V. McMurrayBHF Cardiovascular Research Centre,University of Glasgow,United Kingdom (K.F.D.,P.W.,N.S.,P.D.J.,J.J.V.M.).Division of Cardiac Surgery,St Michael's Hospital,University of Toronto,Canada (S.V.).Department of Cardiology,University Medical Center and University of Groningen,The Netherlands (R.A.D.B.).Montreal Heart Institute,Université de Montréal,Canada (E.O.).AstraZeneca R&D,Gothenburg,Sweden (O.B.,A.H.,A.M.L.,D.L.,D.J.L.,M. Sjöstrand).Rigshospitalet Copenhagen University Hospital,Denmark (L.K.).Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.N.K.).George Institute for Global Health,University of New South Wales,Sydney,Australia (M.N.K.).National University of Cordoba,Argentina (F.A.M.).Wroclaw Medical University,Poland (P.P.).TIMI Study Group,Cardiovascular Division,Brigham and Women's Hospital,and Harvard Medical School,Boston,MA (M.S.S.,D.A.M.).Department of Cardiology,Gentofte University Hospital,Copenhagen,Denmark (M. Schou).Cardiovascular Division,Brigham and Women's Hospital,Boston,MA (S.D.S.).

DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.060511

IF: 37.8

2022-08-18

Circulation

Abstract:Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline. Iron deficiency was defined as a ferritin level <100 ng/mL or a transferrin saturation <20% and a ferritin level 100 to 299 ng/mL. Additional biomarkers of iron metabolism, including soluble transferrin receptor, erythropoietin, and hepcidin were measured at baseline and 12 months after randomization. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 of these participants (43.7%) were iron deficient. The rate of the primary outcome was higher in patients with iron deficiency (16.6 per 100 person-years) compared with those without (10.4 per 100 person-years; P <0.0001). The effect of dapagliflozin on the primary outcome was consistent in iron-deficient compared with iron-replete patients (hazard ratio, 0.74 [95% CI, 0.58–0.92] versus 0.81 [95% CI, 0.63–1.03]; P -interaction=0.59). Similar findings were observed for cardiovascular death, heart failure hospitalization, and all-cause mortality. Transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor increased with dapagliflozin compared with placebo. Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.

cardiac & cardiovascular systems,peripheral vascular disease